The authors aimed to assess whether the humanised anti–interleukin–6 receptor monoclonal antibody, tocilizumab, could attenuate the incidence of acute GVHD.

Interleukin 6 is the main detectable and dysregulated cytokine secreted after allogeneic SCT and its inhibition is a potential new and simple strategy to protect from acute GVHD despite robust immune reconstitution; a randomised, controlled trial assessing tocilizumab in addition to standard GVHD prophylaxis in these patients is warranted.

READ FULL ARTICLE Curated publisher From Mdlinx